Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.” Cancer J 21, no. 4 (July 2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.

PMID
26222085
Full Text

Seligmann, Jenny F., Faye Elliott, Bart Jacobs, Ace Joseph Hatch, Alexander Sibley, Susan Richman, Chen Jiang, et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).” In Journal of Clinical Oncology, 33:3583–3583. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3583.

Full Text

Ahluwalia, Manmeet Singh, Nikolaos Papadantonakis, Vyshak Alva Venur, Cathy Schilero, David M. Peereboom, Glen Stevens, Steven Rosenfeld, et al. “Phase II trial of dovitinib in recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2050–2050. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2050.

Full Text

Keefe, Stephen Michael, Jean H. Hoffman-Censits, Ronac Mamtani, Mary Walicki, Janelle Robinson, Abigail Smith, Orvar Gunnarsson, et al. “HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).” In Journal of Clinical Oncology, 33:4543–4543. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4543.

Full Text

Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, et al. “Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.” Mol Cancer Ther 14, no. 4 (April 2015): 1048–56. https://doi.org/10.1158/1535-7163.MCT-14-0923-T.

PMID
25695956
Full Text

Cushman, Stephanie M., Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon. “Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Clin Cancer Res 21, no. 5 (March 1, 2015): 1078–86. https://doi.org/10.1158/1078-0432.CCR-14-2313.

PMID
25520391
Full Text

Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.” Cancer Chemother Pharmacol 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.

PMID
25527204
Full Text

Rushing, Christel, Anuradha Bulusu, Herbert I. Hurwitz, Andrew B. Nixon, and Herbert Pang. “A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.” Comput Biol Med 57 (February 2015): 123–29. https://doi.org/10.1016/j.compbiomed.2014.11.015.

PMID
25553357
Full Text

Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.

Full Text

Secord, Angeles Alvarez, Andrew B. Nixon, and Herbert I. Hurwitz. “The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.” Gynecol Oncol 135, no. 2 (November 2014): 349–58. https://doi.org/10.1016/j.ygyno.2014.08.033.

PMID
25178997
Full Text

Pages